0.9100
13-2月-25 15:07:49
15 分の遅延
株式
+0.0201
+2.26%
本日の幅
0.8700 - 0.9130
ISIN
N/A
ソース
NASDAQ
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
18 10 2023 08:30:00 提供 Nasdaq GlobeNewswire
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
06 10 2023 08:30:00 提供 Nasdaq GlobeNewswire